Abstract 457: QLS1304, a highly potent and selective KAT6A/B inhibitor treating ER+HER2- breast cancer
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Yuxing Zhang, Chundao Yang, Huijie Guo, Changliang He, Lan Zhang, Ling Li, Mengmeng Zhang, Xuejian Zheng, Ping Chen, Dong Yang, Dongdong Wu, Guqin Shi, Daqing Sun, Wenyuan Qian, Weimei Sun, Weikang Tao
Institution: Qilu Pharmaceutical Co., Ltd. (China)
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409690699